Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Co-CEO and CFO | January 09, 2026 | January 13, 2026 |
| PetVivo Holdings, Inc.PETV · Entity 7591 | Director | May 24, 2021 | May 26, 2021 |
| SAB Biotherapeutics, Inc.BCYP · Entity 5816 | Director | January 11, 2021 | January 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09 | Direct | 49,229 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 49,229 · Balance 49,229 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date.
PetVivo Holdings, Inc.
Report date May 24, 2021 · Filed May 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,384 |
Reported balance
After 2021-04-24 transaction · row 1
1 source rowRow 1 · 2021-04-24 · Purchase · Acquired 3,000 · Balance 67,384 |
SAB Biotherapeutics, Inc.
Report date January 11, 2021 · Filed January 11, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:10 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 49,229 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001493152-26-002036 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Co-CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,229 Underlying: Common Stock · 49,229 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:15 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantWarrants · Derivative | 7,196 | $1.39 Strike: $1.24 | $10,002.44 |
DisclosureSEC source: 0001493152-25-020218 · ownership.xml · derivative · entry 2 Martin James Joseph · CIK 0001510224 · Co-CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,196 Underlying: Common Stock · 7,196 shares Expires 2028-01-28 F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. F1 · derivative.exercise_date: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:15 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 3,598 | $1.39 | $5,001.22 |
DisclosureSEC source: 0001493152-25-020218 · ownership.xml · nonDerivative · entry 1 Martin James Joseph · CIK 0001510224 · Co-CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,167 F1 · security: The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. F2 · balance_after: Includes shares of common stock issuable upon vesting of restricted stock units. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-040900 · ownership.xml · nonDerivative · entry 1 Martin James Joseph · CIK 0001510224 · Co-CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,569 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001493152-23-025084 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Co-CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-07-18 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date. Read SEC document |
| July 25, 2022 Filed Aug 3, 2022 20:03 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-22-021150 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Co- Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-07-25 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 25, 2023 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to continued employment on each applicable vesting date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 20:06 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-21-017327 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-07-16 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date. Read SEC document |
| April 24, 2021 Filed May 26, 2021 16:04 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | PurchaseCommon Stock | 3,000 | $7.00 | $21,000.00 |
DisclosureSEC source: 0001493152-21-012958 · ownership.xml · nonDerivative · entry 1 Martin James Joseph · CIK 0001510224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,384 Read SEC document |
| March 12, 2021 Filed Apr 5, 2021 15:43 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | OtherCommon Stock Warrant · Derivative | 1,117 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-21-007962 · ownership.xml · derivative · entry 4 Martin James Joseph · CIK 0001510224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 1,117 shares Expires 2025-06-30 Read SEC document |
| March 12, 2021 Filed Apr 5, 2021 15:43 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | OtherCommon Stock Warrant · Derivative | 1,227 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001493152-21-007962 · ownership.xml · derivative · entry 3 Martin James Joseph · CIK 0001510224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,617 Underlying: Common Stock · 1,227 shares Expires 2025-03-31 Read SEC document |
| March 12, 2021 Filed Apr 5, 2021 15:43 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | OtherCommon Stock Warrant · Derivative | 1,103 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001493152-21-007962 · ownership.xml · derivative · entry 2 Martin James Joseph · CIK 0001510224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,844 Underlying: Common Stock · 1,103 shares Expires 2024-12-31 Read SEC document |
| March 12, 2021 Filed Apr 5, 2021 15:43 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | OtherCommon Stock | 3,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-007962 · ownership.xml · nonDerivative · entry 1 Martin James Joseph · CIK 0001510224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,384 Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-20-011718 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-06-22 F1 · security: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. F2 · derivative.exercise_date: The stock options vest as follows: 75,000 stock options will vest on the one year anniversary of the grant date and the remaining 75,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 13:00 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001493152-18-013622 · ownership.xml · derivative · entry 1 Martin James Joseph · CIK 0001510224 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-09-20 F1 · security: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. F2 · derivative.exercise_date: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.